Ipilimumab (Yervoy) For Patients With Advanced Melanoma

Posted on: 3rd November 2011

Andrew George has signed EDM2362. Motion reads: “That this House welcomes the campaign by the Karen Clifford Skin Cancer Charity and Factor50 to improve access to treatments for patients with advanced melanoma; notes that in 2008 there were 11,767 new cases of malignant melanoma diagnosed in the UK and that whilst the majority of skin cancers are treatable, malignant melanoma is a particularly aggressive form of skin cancer causing the deaths of over 2,000 people in the UK each year; further notes that melanoma is the second most common cancer among young adults aged between 15 and 34 and that recent data published in the British Journal of Cancer predicts that the incidence rate of melanoma will increase more than any other cancer by 2030, rising by 52 per cent. for both men and women; is therefore deeply concerned that the National Institute for Health and Clinical Excellence(NICE) has issued draft guidance which restricts the use of Ipilimumab (Yervoy) for previously treated advanced malignant melanoma for patients in England and Wales; is furtherconcerned that there have been no licensed treatments for this patient group for over 30 years; and calls on NICE to reconsider its draft guidance for the benefit of patients with advanced melanoma, many of whom have young families.”